74647-39-5

Usage

Uses

Used in Biochemical Research:
4-Phenylpyrimidine-2-carboxylic acid is used as a research compound for exploring its interactions with other organic molecules, which is crucial for understanding its potential applications in biochemistry.
Used in Chemical Reactions:
4-PhenylpyriMidine-2-carboxylic acid is used as a reactant in various chemical processes, leveraging its carboxylic acid group and phenyl group to participate in a range of reactions, contributing to the synthesis of new compounds or the study of reaction mechanisms.
Used in Pharmaceutical Development:
4-Phenylpyrimidine-2-carboxylic acid is used as a building block or a precursor in the development of pharmaceuticals, particularly in the design of new drugs that may have potential therapeutic applications.
Used in Material Science:
In the field of material science, 4-Phenylpyrimidine-2-carboxylic acid may be used as a component in the synthesis of advanced materials, such as polymers or composites, where its unique structure could impart specific properties to the final product.

Upstream product

• 10198-98-8 2-bromo-4-phenylpyrimidine 
• 1201-93-0 1-phenyl-3-dimethylaminoprop-2-enone 
• 98-86-2 acetophenone 
• 1491142-16-5 4-phenylpyrimidine-2-carboxamide 
• 3438-48-0 4-phenylpyrimidine 
• 1131-80-2 (E)-3-(N,N-dimethylamino)-1-phenyl-2-propen-1-one 
• 21203-79-2 2-methyl-6-phenylpyrimidine 

Downstream Products

• 1491142-23-4 N-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]quinoline-4-yl]oxy]phenyl]-4-phenyl-pyrimidine-2-carboxamide 
• 1491142-27-8 N-[3-fluoro-4-[[6-methoxy-7-[3-(1-piperidinyl)propoxy]quinoline-4-yl]oxy]phenyl]-4-phenylpyrimidine-2-carboxamide 
• 1491142-34-7 N-[3-fluoro-4-[[6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinoline-4-yl]oxy]phenyl]-4-phenylpyrimidine-2-carboxamide 
• 1261548-74-6 4-phenylpyrimidine-2-carbonyl chloride 
• 74647-41-9 N,N-dimethyl-6-phenylpyrimidine-2-carboxamide 
• 74647-40-8 methyl 6-phenylpyrimidine-2-carboxylate 

Relevant academic research and scientific papers

QUINOLINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS

Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure (I) and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R1, X, Y1, Y2, Y3 and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.

Discovery of Novel Aryl Carboxamide Derivatives as Hypoxia-Inducible Factor 1α Signaling Inhibitors with Potent Activities of Anticancer Metastasis

In order to discover novel hypoxia-inducible factor 1 (HIF-1) inhibitors for the cancer metastasis treatment, 68 new aryl carboxamide compounds were synthesized and evaluated for their inhibitory effect by dual luciferase-reporter assay. Based on five rounds of investigation on structure-activity relationships step by step, compound 30m was discovered as the most active inhibitor (IC50 = 0.32 μM) with no obvious cytotoxicity (CC50 > 50 μM). It effectively attenuated hypoxia-induced HIF-1α protein accumulation and reduced transcription of vascular epidermal growth factor in a dose-dependent manner, which was further demonstrated by its inhibitory potency on capillary-like tube formation, angiogenesis of zebrafish as well as cellular migration and invasion. Importantly, compound 30m exhibited antimetastatic potency in breast cancer lung metastasis in the mice model, indicating its promising therapeutic potential for prevention and treatment of tumor metastasis. These results definitely merit attention for further rational design of more efficient HIF-1 inhibitors in the future.

Synthesis, activity and docking studies of phenylpyrimidine–carboxamide Sorafenib derivatives

Two series of Sorafenib derivatives bearing phenylpyrimidine–carboxamide moiety (16a–g and 17a–p) were designed, synthesized and evaluated for the IC50values against three cancer cell lines (A549, MCF-7 and PC-3). Two selected compounds (17f and 17n) were further evaluated for the activity against VEGFR2/KDR kinase. More than half of the synthesized compounds showed moderate to excellent activity against three cancer cell lines. Compound 17f showed equal activity to Sorafenib against MCF-7 cell line, with the IC50values of 6.35 ± 0.43 μM. Meanwhile, compound 17n revealed more active than Sorafenib against A549 cell line, with the IC50values of 3.39 ± 0.37 μM. Structure–activity relationships (SARs) and docking studies indicated that the second series (17a–p) showed more active than the first series (16a–g). What's more, the introduction of fluoro atom to the phenoxy part played no significant impact on activity. In addition, the presence of electron-donating on aryl group was benefit for the activity.

Quinoline compound and its preparation method and application (by machine translation)

The invention relates to the general formula I shown quinoline derivatives and their pharmaceutically acceptable salt, hydrate, solvate and prodrug, wherein substituent R1 , R2 , X, Y, Z, n has the meaning given in the specification. The invention also relates to the compounds of the general formula I has strong inhibition of c - Met kinase function, and also relates to the compounds and its pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof in the preparation of the treatment because the c - Met kinase abnormal high expression of diseases caused by the use of the medicaments, in particular in preparing and treating and/or preventing cancer of the use of the medicament. (by machine translation)

Design, synthesis, and structure-activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents

Two series of quinoline derivatives bearing the pyridine/pyrimidine scaffold were synthesized, and evaluated for their c-Met kinase inhibitory activity and antiproliferative activity against 5 cancer cell lines (HT-29, H460, MKN-45, A549, and U87MG) were evaluated in vitro. Most compounds showed moderate to excellent potency, and compared to foretinib, the most promising analog 18b (c-Met half-maximal inhibitory concentration [IC50] = 1.39 nM) showed a 7.3-fold increase in activity against HT-29 cell line in vitro. Structure-activity relationship studies indicated that regulation of the electron density on the pyridine/pyrimidine ring to a proper degree was a key factor in improving the antitumor activity.